02607 SH PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 1.33X | Oper Margin | 3.9% |
|---|---|---|---|
| LT Debt/Equity | 7.1% | Net Margin | 2.0% |
| Total Debt/Equity | 65.2% | Return on Equity | 7.5% |
| Price/Book | 0.52X | Return on Assets | 2.5% |
| (HKD 11.940) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 6,372.01 | 4,841.61 | 4,153.09 | 6,297.95 | 6,229.82 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +31.6 | +16.6 | -34.1 | +1.1 | +16.8 |
| Earnings Per Share (HKD) | 1.718 | 1.307 | 1.122 | 1.808 | 2.192 |
| Earnings Per Share Growth (%) | +31.5 | +16.5 | -38.0 | -17.5 | +16.8 |
| Dividend Per Share (HKD) | 0.522 | 0.404 | 0.441 | 0.664 | 0.492 |
| P/E* (X) | 6.95 | 9.13 | 10.64 | 6.60 | 5.45 |
| Yield (%) | 4.37 | 3.39 | 3.69 | 5.56 | 4.12 |
| Dividend Share (%) | 30.36 | 30.93 | 39.27 | 36.71 | 22.45 |
| Book NAV (HKD) | 22.780 | 20.558 | 20.395 | 20.335 | 21.242 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 283,580 | 275,251 | +3.0 | 260,295 |
| Operating Result | 9,500 | 7,431 | +27.8 | 7,445 |
| Associates | 284.473 | 521.909 | -45.5 | 129.329 |
| Profit Before Taxation | 9,820 | 8,020 | +22.4 | 7,054 |
| Taxation | 2,846 | 2,150 | +32.4 | 1,888 |
| Profit /( Loss) After Taxation | 6,974 | 5,870 | +18.8 | 5,167 |
| Minority Interests | 1,249 | 1,317 | -5.2 | 1,399 |
| Net Profit | 5,725 | 4,553 | +25.7 | 3,768 |
| Earnings Per Share () | 1.7183 | 1.3071 | +31.5 | 1.1221 |
| Dividend Per Share () | 0.5217 | 0.4043 | +29.0 | 0.4407 |
| Announcement Date | 2026-03-30 | 2025-03-27 | NA | 2024-03-28 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
